Key result
Takayasu arteritis management centers on corticosteroids combined with steroid-sparing immunosuppressive and biologic therapies.
Answers are grounded in this paper and cite their sources.
Takayasu arteritis (TA or TAK) is a chronic large vessel vasculitis with predilection to affect the aorta and its branches. The new 2022 ACR/EULAR classification criteria for Takayasu arteritis incorporated imaging characteristics as an absolute requirement. ESR and CRP fails in accuracy as disease activity markers. Pentraxin 3 appears to be a relatively superior biomarker, which correlates with ITAS 2010 as per several studies. PET-CT is also increasingly being studied for assessing disease activity with variable results. The management of TAK involves use of steroids with upfront steroid sparing immunosuppressive agents. MMF is one such conventional DMARD/immunosuppressant with good efficacy and better safety profile, as reported in various cohort studies. Tocilizumab is proved to be a rapid remission inducing agent in refractory Takayasu arteritis in observational studies. TNF inhibitors in many uncontrolled studies showed good responses, and there is a need for good RCTs for confirmation. JAK inhibitors have also been used with success in a few reports.
No takes yet. Share an insight, caveat, or question.
AS et al. (2023) conducted a review in Takayasu arteritis. Diagnosis and management strategies was evaluated. Management of Takayasu arteritis relies on corticosteroids alongside steroid-sparing agents such as mycophenolate mofetil, tocilizumab, TNF inhibitors, and JAK inhibitors.
Synapse has enriched 10 related papers. Consider them for comparative context: